Application Note

Establishing A Robust Workflow To Identify High-Performing GOCHO™ Clones

Source: Cytiva

By Sheffali Dash, Michelle Sabourin, Jichu Li, and Paula Ravnikar

Cytiva 1 48201_2

Cell line development is typically on the critical path of drug development. It’s a complex, labor intensive, and multistep process. Our cell line development platform uses the GOCHO™ host cell line to minimize the risk and timeline to develop high-performing clones suitable for manufacturing. However, multiple minipools and/or clones are often lost in the expansion process during the transition from static to suspension culture.

Learn about a study exploring an alternative approach to reduce the losses of minipools and clones to improve the overall process result. In the cell line development workflow, minipool selection is initiated 48 h after transfection. Through a series of expansion steps, minipools or clones are expanded to progressively larger volumes and productivity is ranked. The parameters to use for optimal expansion and for timing the transition from static to shaking culture was investigated. With the new workflow described, the overall timeline was improved by ~ 2 weeks and multiple clones producing > 4 g/L in a fed-batch culture were readily obtained. Explore this new workflow and how it is more robust than our previous version and increases our chances of delivering highly productive clones.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online